Author: jschoales
-
-
Patient Partner Learning Annex Informational Session
3CTN is excited to announce that we are holding an informational session on June 26, 2024 (1 – 2 pm EDT) for our recently launched Patient Partner Learning Annex tool.
-
impACCT Virtual Rounds Spring Session 2024
When: Thursday, May 23, 2024 12:00 pm -1:00 pm EDT Featured Trial (CHUQ) BicaBCa: A phase II randomized trial of bicalutamide in patients receiving intravesical BCG for non-muscle invasive bladder cancer (NCT05327647) Speaker: Dr. Paul Toren, MD, Associate Professor, Department of Surgery – Faculty of Medicine, Université Laval Speaker: Dr. Joe Pater, MD, Emeritus Professor,
-
EDI Toolkit and Resources
We recently add a new page to our website! The Equity, Diversity and Inclusion (EDI) in Clinical Trials contains EDI resources developed by 3CTN and our recently completed EDI Toolkit.
-
-
A Tool for Patient Partner Development
Embedding Patient and Public Involvement (PPI) as a means for helping assure patient values and perspectives are reflected in clinical trials conduct has been a founding priority of the Canadian Cancer Clinical Trials Network (3CTN). Our community of Patient Representatives guide and support trial activities locally at cancer centres and centrally through participation in Network
-
3CTN’s Executive Director talks CRAFT DCT model development
Stephen Sundquist joins the Decentralized: The Decentralized Trials and Research Podcast to talk about the CRAFT DCT model development and implementation strategy and Bianka Courcelle from CHU Sainte-Justine, shares the PI site perspective in implementing these trials.
-
Canada needs a national system for cancer clinical trials
Toronto Star – Clinical trials are the most effective means of ensuring we have better cancer treatments. Such an investment would help overcome many hurdles facing clinical trials – from underfunding and suboptimal testing capacity to inefficient and costly regulatory processes. By Janet Dancey Contributor “A bad system will beat a good person every time.” William Edwards Deming
-
impACCT Virtual Rounds Winter Session 2024
When: Thursday, March 7, 2024 12:00 pm -1:15 pm EST Trial #1: OCOG-2022-ROSALIE: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy https://clinicaltrials.gov/study/NCT05866458 Speaker: Dr. Elena Parvez, MD, Assistant Professor, Department of Surgery, McMaster University; Surgical Oncologist at the Juravinski Hospital and Cancer
-
2022-23 3CTN Impact Report
Check out the accomplishments of Network Sites and the 3CTN Coordinating Centre.